Loading…
Employees: 1,331
Size Berry Genomics (000710.SZ) is a China Health Care company (Biotechnology) with a market value of $504M, the 3850th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥9.53 on 6 Nov 2026.
Performance Over six months the shares fell 4.6%, against -14.2% for the median peer and -16.4% for the China market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue fell 2.2% over the last twelve months (peer median -11.0%); the operating margin is -24.2% (peer median -3.6%).
Valuation It trades at 3.8× enterprise value to sales against a peer median of 8.0× (3rd cheapest of 16).
Capital Return on invested capital runs 15.4 points below its cost of capital (7.9% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥921M | CN¥928M | CN¥1.07B | CN¥1.15B | CN¥1.36B |
| Revenue growth | — | -13% | -7% | -16% | — |
| Gross profit | CN¥414M | CN¥326M | CN¥440M | CN¥441M | CN¥509M |
| EBITDA | n/a | -CN¥78.6M | -CN¥21.4M | -CN¥76.2M | -CN¥11.7M |
| Net income | -CN¥247M | -CN¥197M | -CN¥192M | -CN¥427M | -CN¥249M |
| Free cash flow | -CN¥86.7M | -CN¥5.08M | CN¥31.2M | CN¥62.9M | -CN¥50.3M |
| Capital expenditure | CN¥48.5M | CN¥75.7M | CN¥56.8M | CN¥55.1M | CN¥73.3M |
| Total debt | CN¥286M | CN¥273M | CN¥190M | CN¥319M | CN¥368M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000710.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.2% | -13.5% | 7th highest of 21 |
| 6-month return | -4.6% | -14.2% | 6th highest of 20 |
| Distance from 52-week high | -39.0% | -42.2% | 9th highest of 21 |
| Revenue growth (TTM) | -2.2% | -11.0% | 7th highest of 15 |
| Operating margin | -24.2% | -3.6% | 8th lowest of 16 |
| EV / Sales | 3.8× | 8.0× | 3rd cheapest of 16 |
| ROIC minus cost of capital | -15.4 pp | -5.8 pp | 7th lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Berry Genomics 000710.SZ | China | $504M | -5% | -2% | -24% | 3.8× | n/a | n/a |
| Qurient 115180.KS | South Korea | $503M | -59% | -20% | -517% | 98.9× | n/a | n/a |
| Crescent Biopharma CBIO | United States | $503M | -28% | n/a | -1,418% | 28.3× | n/a | n/a |
| DiaMedica Therapeutics DMAC | United States | $505M | +48% | n/a | n/a | n/a | n/a | n/a |
| Neurogene NGNE | United States | $506M | -18% | -100% | n/a | n/a | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $507M | -11% | -1% | 26% | 13.7× | n/a | n/a |
| HanchorBio 7827.TW | Taiwan | $511M | n/a | n/a | -225% | 48.0× | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $526M | -25% | +4% | 8% | 8.0× | n/a | n/a |
| Scinopharm Taiwan 1789.TW | Taiwan | $482M | -1% | -5% | -4% | 5.2× | 15.2% | +0.5% |
| CHO Pharma 6586.TWO | Taiwan | $480M | +57% | -47% | -17,694% | 8,168.1× | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +12% | n/a | n/a | n/a | n/a | n/a |
| Liaoning Dingjide Petrochemical 603255.SS | China | $530M | -15% | +70% | 5% | 5.4× | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $531M | -33% | +2% | 17% | 2.2× | n/a | n/a |
| Valneva VLA.PA | France | $534M | -2% | -27% | -87% | 4.0× | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $537M | -14% | -17% | 0% | 7.0× | 31.6% | +7.0% |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $469M | -13% | n/a | n/a | n/a | n/a | n/a |
| Shanghai ZJ Bio-Tech 688317.SS | China | $468M | -16% | -18% | -75% | 5.2× | 6.0% | -62.3% |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $468M | -27% | +286% | 68% | 2.5× | -14.9% | -36.1% |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $467M | -5% | +44% | 10% | 18.0× | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $466M | -5% | n/a | n/a | n/a | n/a | n/a |
| Shattuck Labs STTK | United States | $464M | -33% | -67% | -5,571% | 258.1× | n/a | n/a |